Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans

Translated title of the contribution: Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans

A. Baars, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

A 37-year-old man was diagnosed with metastatic dermatofibrosarcoma. Dermatofibrosarcoma protuberans is a rare skin tumour with a strong tendency for infiltrative growth, resulting in a high rate of local recurrences; metastatic disease develops in approximately 5% of patients, especially in the lungs. On the basis of some recent publications about the use of imatinib in patients with dermatofibrosarcoma, the patient was prescribed this drug. The treatment resulted in a partial response. Imatinib is the first registered selective tyrosine-kinase inhibitor for treatment of chronic myeloid leukaemia. The inhibition of tyrosine kinase interrupts the proliferative signal transduction.

Original languageDutch
Pages (from-to)2072-2076
Number of pages5
JournalNederlands Tijdschrift voor Geneeskunde
Volume147
Issue number42
StatePublished - Oct 18 2003
Externally publishedYes

Fingerprint

Dermatofibrosarcoma
Protein-Tyrosine Kinases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Signal Transduction
Therapeutics
Recurrence
Lung
Skin
Growth
Pharmaceutical Preparations
Imatinib Mesylate
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans. / Baars, A.; Pinedo, H. M.

In: Nederlands Tijdschrift voor Geneeskunde, Vol. 147, No. 42, 18.10.2003, p. 2072-2076.

Research output: Contribution to journalArticle

@article{a716e8a3582a46b493d2b0f38733829b,
title = "Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een pati{\"e}nt met gemetastaseerd dermatofibrosarcoma protuberans",
abstract = "A 37-year-old man was diagnosed with metastatic dermatofibrosarcoma. Dermatofibrosarcoma protuberans is a rare skin tumour with a strong tendency for infiltrative growth, resulting in a high rate of local recurrences; metastatic disease develops in approximately 5{\%} of patients, especially in the lungs. On the basis of some recent publications about the use of imatinib in patients with dermatofibrosarcoma, the patient was prescribed this drug. The treatment resulted in a partial response. Imatinib is the first registered selective tyrosine-kinase inhibitor for treatment of chronic myeloid leukaemia. The inhibition of tyrosine kinase interrupts the proliferative signal transduction.",
author = "A. Baars and Pinedo, {H. M.}",
year = "2003",
month = "10",
day = "18",
language = "Dutch",
volume = "147",
pages = "2072--2076",
journal = "Nederlands Tijdschrift voor Geneeskunde",
issn = "0028-2162",
publisher = "Bohn Stafleu van Loghum",
number = "42",

}

TY - JOUR

T1 - Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans

AU - Baars, A.

AU - Pinedo, H. M.

PY - 2003/10/18

Y1 - 2003/10/18

N2 - A 37-year-old man was diagnosed with metastatic dermatofibrosarcoma. Dermatofibrosarcoma protuberans is a rare skin tumour with a strong tendency for infiltrative growth, resulting in a high rate of local recurrences; metastatic disease develops in approximately 5% of patients, especially in the lungs. On the basis of some recent publications about the use of imatinib in patients with dermatofibrosarcoma, the patient was prescribed this drug. The treatment resulted in a partial response. Imatinib is the first registered selective tyrosine-kinase inhibitor for treatment of chronic myeloid leukaemia. The inhibition of tyrosine kinase interrupts the proliferative signal transduction.

AB - A 37-year-old man was diagnosed with metastatic dermatofibrosarcoma. Dermatofibrosarcoma protuberans is a rare skin tumour with a strong tendency for infiltrative growth, resulting in a high rate of local recurrences; metastatic disease develops in approximately 5% of patients, especially in the lungs. On the basis of some recent publications about the use of imatinib in patients with dermatofibrosarcoma, the patient was prescribed this drug. The treatment resulted in a partial response. Imatinib is the first registered selective tyrosine-kinase inhibitor for treatment of chronic myeloid leukaemia. The inhibition of tyrosine kinase interrupts the proliferative signal transduction.

UR - http://www.scopus.com/inward/record.url?scp=0142026838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142026838&partnerID=8YFLogxK

M3 - Article

C2 - 14606355

AN - SCOPUS:0142026838

VL - 147

SP - 2072

EP - 2076

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

SN - 0028-2162

IS - 42

ER -